A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV)

Inclusion criteria

• ✓. Participant must be 18 to 70 years of age inclusive, at the time of signing the informed consent.
• ✓. Must be on uninterrupted current regimen for at least 6 months prior to Screening. Any prior switch, defined as a change of a single drug or multiple drugs simultaneously, must have occurred due to tolerability/safety, access to medications, or convenience/simplification, and must NOT have been done for treatment failure (HIV-1 RNA ≥200 c/mL).
• ✓. Documented evidence of at least two plasma HIV-1 RNA measurements \<50 c/mL in the 12 months prior to Screening: one within the 6 to 12-month window, and one within 6 months prior to Screening;
• ✓. Plasma HIV-1 RNA \<50 c/mL at Screening;
• ✓. Screening CD4+ T-cell count ≥350 cells/mm3:
• ✓. Body weight \>=50 kg to \<=115 kg.
• ✓. Male and/or female Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies, assuring minimal contraception requirements noted below.
• ✓. Participants who are female at birth are eligible to participate if at least one of the following conditions applies:

Exclusion criteria